Effect of sarilumab on unacceptable pain and inflammation control in Japanese patients with moderately-to-severely active rheumatoid arthritis: <i>Post hoc</i> analysis of a Phase III study (KAKEHASI)
Yoshiya Tanaka(University of Occupational and Environmental Health Japan), Hideto Kameda(Toho University), Hubert van Hoogstraten(Sanofi (United States)), Toshiya Takahashi(Tohoku University), Naoto Kato(Jichi Medical University)
Cited by 5
Related Papers
Trial of Anifrolumab in Active Systemic Lupus Erythematosus
|New England Journal of Medicine|2019|1.3k
EULAR recommendations for the management of systemic lupus erythematosus: 2023 update
|Annals of the Rheumatic Diseases|2023|913
Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis
|Annals of the Rheumatic Diseases|2007|413